2,454 followers
Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib. #lymphoma #lymsm https://t.co/5URzDzE9G2
Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib. #lymphoma #lymsm https://t.co/5URzDzE9G2
Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib. #lymphoma #lymsm https://t.co/5URzDzE9G2